It has been reported that SIRT6 overexpression in primary HCC tumors is correlated with tumor size and grade [42], while CEAPA, combined with KIF20A, PLK1, and NCAPG, form a 4-gene expression prognostic signature, which can be used to predict prognosis and to define a subgroup of high-risk HCC patients who could potentially benefit from JmjC inhibitor therapy [43]. This evidence concerns the gene SIRT6 and hepatocellular carcinoma.